Journal Mobile Options
Table of Contents
Vol. 72, No. 3, 2005
Issue release date: April 2005
Pathobiology 2005;72:133–138

A Single Nucleotide Polymorphism in the 5′ Untranslated Region of the EGF Gene Is Associated with Occurrence and Malignant Progression of Gastric Cancer

Hamai Y. · Matsumura S. · Matsusaki K. · Kitadai Y. · Yoshida K. · Yamaguchi Y. · Imai K. · Nakachi K. · Toge T. · Yasui W.
Departments of aMolecular Pathology and bMedicine and Molecular Science, Hiroshima University Graduate School of Biomedical Sciences, cDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, and dDepartment of Radiobiology/Molecular Epidemiology, Radiation Effects Research Foundation, Hiroshima; eDepartment of Surgery, Hofu Institute of Gastroenterology, Yamaguchi, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: Epidermal growth factor (EGF) has many biological functions and plays an important role in the progression of various tumors including gastric cancer. An A-G single nucleotide polymorphism (SNP) at position 61 in the 5′-untranslated region (UTR) of the EGF gene has recently been reported to be associated with different levels of EGF production. We examined whether this polymorphism is correlated with the development and malignant phenotypes of gastric cancer. Methods: The study population included 200 gastric cancer patients and 230 healthy control subjects. The SNP in the 5′-UTR of the EGF gene was analyzed by polymerase chain reaction-restriction fragment length polymorphism. Results: The A allele was significantly less frequent in patients than in controls (p = 0.01). Individuals with the A/A or A/G genotype showed a significantly lower risk of gastric cancer than those with the G/G genotype [adjusted odds ratio (OR) = 0.56], whereas the same genotypes were associated with malignant progression of this cancer, e.g. deeper tumor invasion, increased lymph node metastasis and advanced clinical stage, and histological classification in gastric cancer patients (adjusted OR = 1.80, 1.98, 2.26 and 1.89, respectively). Conclusions: Our findings suggest that the A-G polymorphism of EGF is involved not only in the occurrence but also in the malignant progression of gastric cancer.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Pisani P, Parkin DM, Bray F, Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18–29.
  2. Kelley JR, Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1–9.
  3. Hohenberger P, Gretschel S: Gastric cancer. Lancet 2003;362:305–315.
  4. Dunbier A, Guilford P: Hereditary diffuse gastric cancer. Adv Cancer Res 2001;83:55–65.
  5. Correa P: Human gastric carcinogenesis: A multistep and multifactorial process –First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735–6740.
  6. Tahara E: Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol 1993;119:265–272.
  7. Stadtlander CT, Waterbor JW: Molecular epidemiology, pathogenesis and prevention of gastric cancer. Carcinogenesis 1999;20:2195–2208.
  8. Neugut AI, Hayek M, Howe G: Epidemiology of gastric cancer. Semin Oncol 1996;23:281–291.
  9. Malaty HM, Engstrand L, Pedersen NL, Graham DY: Helicobacter pylori infection: Genetic and environmental influences. A study of twins. Ann Intern Med 1994;120:982–986.
  10. Yasui W, Yokozaki H, Fujimoto J, Naka K, Kuniyasu H, Tahara E: Genetic and epigenetic alterations in multistep carcinogenesis of the stomach. J Gastroenterol 2000;35(suppl 12):111–115.

    External Resources

  11. Werner M, Becker KF, Keller G, Hofler H: Gastric adenocarcinoma: Pathomorphology and molecular pathology. J Cancer Res Clin Oncol 2001;127:207–216.
  12. Gonzalez CA, Sala N, Capella G: Genetic susceptibility and gastric cancer risk. Int J Cancer 2002;100:249–260.
  13. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW: Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 2003;284:31–53.
  14. Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 2000;19:3159–3167.
  15. Laurence DJ, Gusterson BA: The epidermal growth factor. A review of structural and functional relationships in the normal organism and in cancer cells. Tumour Biol 1990;11:229–261.
  16. Singletary SE, Baker FL, Spitzer G, Tucker SL, Tomasovic B, Brock WA, Ajani JA, Kelly AM: Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res 1987;47:403–406.
  17. Stoscheck CM, King LE Jr: Role of epidermal growth factor in carcinogenesis. Cancer Res 1986 46:1030–1037.
  18. Barnard JA, Beauchamp RD, Russell WE, Dubois RN, Coffey RJ: Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology 1995;108:564–580.
  19. Yoshida K, Kyo E, Tsuda T, Tsujino T, Ito M, Niimoto M, Tahara E: EGF and TGF-alpha, the ligands of hyperproduced EGFR in human esophageal carcinoma cells, act as autocrine growth factors. Int J Cancer 1990;45:131–135.
  20. Coyle WJ, Sedlack RE, Nemec R, Peterson R, Duntemann T, Murphy M, Lawson JM: Eradication of Helicobacter pylori normalizes elevated mucosal levels of epidermal growth factor and its receptor. Am J Gastroenterol 1999;94:2885–2889.
  21. Ito R, Kitadai Y, Kyo E, Yokozaki H, Yasui W, Yamashita U, Nikai H, Tahara E: Interleukin 1 alpha acts as an autocrine growth stimulator for human gastric carcinoma cells. Cancer Res 1993;53:4102–4106.
  22. Ito R, Yasui W, Kuniyasu H, Yokozaki H, Tahara E: Expression of interleukin-6 and its effect on the cell growth of gastric carcinoma cell lines. Jpn J Cancer Res 1997;88:953–958.
  23. Yasui W, Hata J, Yokozaki H, Nakatani H, Ochiai A, Ito H, Tahara E: Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int J Cancer 1988;41:211–217.
  24. Yasui W, Sumiyoshi H, Hata J, Kameda T, Ochiai A, Ito H, Tahara E: Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 1988;48:137–141.
  25. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, Kiyama T, Yoshiyuki T, Nishi K, Matsukura N: Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995;75(6 suppl):1418–1425.
  26. Tahara E, Sumiyoshi H, Hata J, Yasui W, Taniyama K, Hayashi T, Nagae S, Sakamoto S: Human epidermal growth factor in gastric carcinoma as a biologic marker of high malignancy. Jpn J Cancer Res 1986;77:145–152.
  27. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, Hutchinson PE, Osborne JE, Lear JT, Smith AG, Hutchinson IV: Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002;359:397–401.
  28. McCarron SL, Bateman AC, Theaker JM, Howell WM: EGF +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma. Int J Cancer 2003;107:673–675.
  29. Amend KL, Elder JT, Tomsho LP, Bonner JD, Johnson TM, Schwartz J, Berwick M, Gruber SB: EGF gene polymorphism and risk of incident primary melanoma. Cancer Res 2004;64:2668–2672.
  30. Bhowmick DA, Zhuang Z, Wait SD, Weil RJ: A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res 2004;64:1220–1223.
  31. Sobin LH, Wittekind CH (eds): TNM Classification of Malignant Tumors, ed 6. New York, Wiley-Liss, 2002, pp 65–68.
  32. Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand 1965;64:31–49.
  33. Gebhardt F, Zanker KS, Brandt B: Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999;274:13176–13180.
  34. Buerger H, Gebhardt F, Schmidt H, Beckmann A, Hutmacher K, Simon R, Lelle R, Boecker W, Brandt B: Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 2000;60:854–857.
  35. Buerger H, Packeisen J, Boecker A, Tidow N, Kersting C, Bielawski K, Isola J, Yatabe Y, Nakachi K, Boecker W, Brandt B: Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence – First results of an inter-ethnic breast cancer study. J Pathol 2004;203:545–550.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50